Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 43
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 2101 | MEDICENNA THERAPEUTICS | 7 | 00% | 0 | 7 | 2022–2026 |
| 2102 | MEIJI SEIKA PHARMA | 7 | 00% | 0 | 7 | 2022–2025 |
| 2103 | MERXIN | 7 | 00% | 0 | 7 | 2024–2026 |
| 2104 | MESDAN | 7 | 00% | 0 | 7 | 2022–2025 |
| 2105 | MEXICHEM UK | 7 | 228.6% | 1 | 4 | 2022–2025 |
| 2106 | MEYER BURGER GERMANY | 7 | 00% | 0 | 7 | 2022–2026 |
| 2107 | MINCON INTERNATIONAL | 7 | 00% | 0 | 7 | 2022–2025 |
| 2108 | MITSUMI ELECTRIC | 7 | 00% | 0 | 7 | 2023–2025 |
| 2109 | MOLECULAR PARTNERS | 7 | 00% | 2 | 5 | 2022–2025 |
| 2110 | NANOVATION THERAPEUTICS | 7 | 00% | 0 | 7 | 2023–2025 |
| 2111 | NAVIGO PROTEINS | 7 | 114.3% | 0 | 6 | 2021–2025 |
| 2112 | NAYAX | 7 | 00% | 4 | 3 | 2023–2025 |
| 2113 | NEO CHEMICALS OXIDES | 7 | 00% | 0 | 7 | 2023–2025 |
| 2114 | NEO MEDICAL | 7 | 00% | 0 | 7 | 2022–2025 |
| 2115 | NEUROVIGIL | 7 | 00% | 0 | 7 | 2025–2026 |
| 2116 | NEW TEC INTEGRATION XIAMEN | 7 | 00% | 0 | 7 | 2022–2025 |
| 2117 | NEWLEAF SYMBIOTICS | 7 | 00% | 0 | 7 | 2022–2025 |
| 2118 | NIHON MEDI PHYSICS | 7 | 00% | 0 | 7 | 2022–2024 |
| 2119 | NIPPON SHEET GLASS | 7 | 00% | 0 | 7 | 2022–2026 |
| 2120 | NOAHTRON INTELLIGENCE MEDTECH HANGZHOU | 7 | 00% | 2 | 5 | 2022–2024 |
| 2121 | NORDEX ENERGY SPAIN U | 7 | 00% | 0 | 7 | 2024–2026 |
| 2122 | NOVA CHEMICALS INTERNATIONAL | 7 | 114.3% | 3 | 3 | 2022–2024 |
| 2123 | NOVA TECH ENGINEERING | 7 | 00% | 0 | 7 | 2022–2026 |
| 2124 | NUTROMICS TECHNOLOGY PTY | 7 | 00% | 0 | 7 | 2025–2025 |
| 2125 | OBERTHUR FIDUCIAIRE | 7 | 114.3% | 0 | 6 | 2022–2025 |
| 2126 | OFFICINE MACCAFERRI | 7 | 114.3% | 0 | 6 | 2022–2026 |
| 2127 | OPTOS | 7 | 228.6% | 1 | 4 | 2022–2024 |
| 2128 | OPTOTUNE SWITZERLAND | 7 | 342.9% | 0 | 4 | 2021–2026 |
| 2129 | OQMENTED | 7 | 00% | 0 | 7 | 2023–2024 |
| 2130 | OSPEDALE SAN RAFFAELE S R L | 7 | 00% | 2 | 5 | 2022–2025 |
| 2131 | OSTOMYCURE AS | 7 | 228.6% | 0 | 5 | 2021–2026 |
| 2132 | OTHAIR PROTHENA | 7 | 00% | 0 | 7 | 2022–2026 |
| 2133 | OXFORD NANOPORE TECHNOLOGIES | 7 | 00% | 0 | 7 | 2022–2025 |
| 2134 | PATTERN BIOSCIENCE | 7 | 00% | 0 | 7 | 2022–2024 |
| 2135 | PERKINELMER HEALTH SCIENCES | 7 | 114.3% | 5 | 1 | 2022–2022 |
| 2136 | PETAL CLOUD TECHNOLOGY | 7 | 571.4% | 1 | 1 | 2022–2022 |
| 2137 | PICOMOLE | 7 | 00% | 0 | 7 | 2022–2023 |
| 2138 | PIVOT BIO | 7 | 00% | 1 | 6 | 2022–2024 |
| 2139 | PLASTIC OMNIUM NEW ENERGIES FRANCE | 7 | 00% | 0 | 7 | 2023–2025 |
| 2140 | PPC BROADBAND FIBER | 7 | 114.3% | 0 | 6 | 2022–2024 |
| 2141 | PRIMETALS TECHNOLOGIES USA | 7 | 114.3% | 1 | 5 | 2022–2025 |
| 2142 | PROMETHEUS BIOSCIENCES | 7 | 00% | 0 | 7 | 2022–2025 |
| 2143 | PULPAC | 7 | 00% | 0 | 7 | 2023–2026 |
| 2144 | RAPID MICRO BIOSYSTEMS | 7 | 00% | 0 | 7 | 2023–2025 |
| 2145 | RECKITT BENCKISER VANISH | 7 | 00% | 2 | 5 | 2022–2025 |
| 2146 | RESMED PTY | 7 | 00% | 2 | 5 | 2022–2025 |
| 2147 | RF360 EUROPE | 7 | 00% | 0 | 7 | 2022–2023 |
| 2148 | ROBLOX | 7 | 571.4% | 0 | 2 | 2022–2023 |
| 2149 | ROSENBERGER HOCHFREQUENZTECHNIK KG | 7 | 00% | 0 | 7 | 2023–2025 |
| 2150 | RUAG AMMOTEC | 7 | 114.3% | 3 | 3 | 2022–2023 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →